SGMT
USDSagimet Biosciences Inc. Series A Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$7.530
Máximo
$7.670
Mínimo
$7.020
Volumen
0.13M
Fundamentos de la Empresa
Capitalización de Mercado
244.6M
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
0.57M
Bolsa
NGM
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announced completion of
Clear Street Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $29
Clear Street analyst Kaveri Pohlman initiates coverage on Sagimet Biosciences with a Buy rating and announces Price Target of $29.
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
Acciones Relacionadas
AIZN
Assurant Inc. 5.25% Subordinated Notes due 2061
CRS
Carpenter Technology Corporation
SAJ
Saratoga Investment Corp 8.00% Notes due 2027
DHR
Danaher Corporation
OFSSH
OFS Capital Corporation 4.95% Notes due 2028
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.